Business Context and Reporting Period
This Form 8-K is filed by Nuvilex, Inc. (referenced in metadata as Pharmacyte Biotech, Inc.) on July 17, 2013. The report details material definitive agreements entered into on July 10, 2013, with an effective date of June 25, 2013, and significant changes to executive compensation and roles.
Key Financial Metrics and Transactions
- Acquisition Cost: The Company paid $1.5 million USD in cash to acquire 100% of the equity interests in Bio Blue Bird AG (BBB).
- Funding Source: The acquisition was funded through a private placement of 12,000,000 shares of restricted common stock at $0.125 per share.
- Equity Interest: In addition to BBB, the Company received a 14.5% equity interest in SG Austria Private Limited.
- Debt Status: BBB is reported as a debt-free wholly-owned subsidiary.
- Executive Compensation:
- Dr. Robert Ryan (CEO): Annual salary of $60,000 plus 2,400,000 restricted shares.
- Dr. Gerald W. Crabtree (COO): Annual salary of $60,000 (commencing Sept 1, 2013) plus 1,200,000 restricted shares.
- Patricia Gruden (Interim CFO): No compensation for this role.
The filing text does not provide clear values for total revenue, net profit, operating cash flow, or overall company liquidity beyond the specific transaction details.
Material Changes
- Asset Acquisition: Completed acquisition of BBB, which provides exclusive worldwide licenses for living-cell encapsulation-based cancer treatment technology licensed from Bavarian Nordic.
- Licensing: Secured an exclusive worldwide license for the "Cell-In-A-Box" trademark and associated technology from Austrianova Singapore Pte Ltd.
- Contract Modification: The Third Addendum modified the original 2011 Asset Purchase Agreement; previously planned "Escrow Shares" (100,000,000 shares) were returned to the Company's treasury rather than issued to SG Austria.
- Management Changes: Dr. Robert Ryan resigned as Interim CFO to focus on CEO duties; Patricia Gruden appointed as Interim CFO.
Outlook, Risks, and Management Commentary
Management commentary indicates a strategic shift toward oncology and disease treatment via encapsulation technology. The acquisition of BBB and the new licensing agreement are intended to expand the Company's interests in living-cell encapsulation and virus-expressing cell treatments. The filing notes that the disclosures regarding the transactions are qualified by reference to the full text of the exhibits.
Investor Verification Checklist
- Verify the closing status and regulatory approval of the $1.5 million acquisition of Bio Blue Bird AG.
- Confirm the terms and validity of the exclusive worldwide licenses obtained from Bavarian Nordic and Austrianova Singapore Pte Ltd.
- Review the full text of the Third Addendum to the Asset Purchase Agreement (Exhibit 10.1) to understand the return of Escrow Shares.
- Assess the dilution impact of the 12,000,000 shares issued for funding and the 3,600,000 restricted shares issued to executives.
- Confirm the Company's current cash position post-acquisition, as the filing does not explicitly state remaining liquidity.